89 related articles for article (PubMed ID: 15147608)
1. Critical evaluation of p53 as a prognostic marker in ovarian cancer.
Hall J; Paul J; Brown R
Expert Rev Mol Med; 2004 May; 6(12):1-20. PubMed ID: 15147608
[TBL] [Abstract][Full Text] [Related]
2. [Chemoresistance in ovarian cancer. State of the art and future prospects].
Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
[TBL] [Abstract][Full Text] [Related]
3. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract][Full Text] [Related]
5. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.
Mezzanzanica D; Balladore E; Turatti F; Luison E; Alberti P; Bagnoli M; Figini M; Mazzoni A; Raspagliesi F; Oggionni M; Pilotti S; Canevari S
Clin Cancer Res; 2004 Aug; 10(15):5202-14. PubMed ID: 15297424
[TBL] [Abstract][Full Text] [Related]
6. TP53 status and response to chemotherapy in breast cancer.
Bertheau P; Espié M; Turpin E; Lehmann J; Plassa LF; Varna M; Janin A; de Thé H
Pathobiology; 2008; 75(2):132-9. PubMed ID: 18544968
[TBL] [Abstract][Full Text] [Related]
7. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas.
Høgdall EV; Christensen L; Høgdall CK; Frederiksen K; Gayther S; Blaakaer J; Jacobs IJ; Kjaer SK
APMIS; 2008 May; 116(5):400-9. PubMed ID: 18452430
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.
Song YC; Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():26-34. PubMed ID: 17404014
[TBL] [Abstract][Full Text] [Related]
9. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
Abedini MR; Muller EJ; Brun J; Bergeron R; Gray DA; Tsang BK
Cancer Res; 2008 Jun; 68(12):4511-7. PubMed ID: 18559494
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
[TBL] [Abstract][Full Text] [Related]
13. Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance.
Popat S; Wort R; Houlston RS
BMC Cancer; 2006 Jun; 6():150. PubMed ID: 16753067
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
15. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive significance of p53 mutation in aggressive B-cell lymphoma.
Ichikawa A
Int J Hematol; 2000 Apr; 71(3):211-20. PubMed ID: 10846825
[TBL] [Abstract][Full Text] [Related]
17. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress.
Li J; Tan J; Zhuang L; Banerjee B; Yang X; Chau JF; Lee PL; Hande MP; Li B; Yu Q
Cancer Res; 2007 Dec; 67(23):11317-26. PubMed ID: 18056458
[TBL] [Abstract][Full Text] [Related]
18. Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer.
Chan JK; Loizzi V; Magistris A; Lin F; Rutgers J; Osann K; Disaia PJ; Berman ML
Clin Cancer Res; 2004 Dec; 10(24):8538-43. PubMed ID: 15623636
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
20. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]